Atlas Trials

Stage III Uterine Corpus Cancer AJCC v7

11 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Stage III Uterine Corpus Cancer AJCC v7

RecordFirmDate
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers (NCT03345784)National Cancer Institute (NCI)2018-05-29
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer (NCT02684227)M.D. Anderson Cancer Center2016-08-24
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer (NCT03902379)Rutgers, The State University of New Jersey2016-07-27
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (NCT02208375)M.D. Anderson Cancer Center2014-11-11
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (NCT01970722)City of Hope Medical Center2014-05-19
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer (NCT02065687)Gynecologic Oncology Group2014-03-17
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (NCT01440998)National Cancer Institute (NCI)2011-09-20
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery (NCT00410553)National Cancer Institute (NCI)2006-11-14
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer (NCT00006903)Gynecologic Oncology Group2004-08-30
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT00006089)National Cancer Institute (NCI)2000-09-18

Track Stage III Uterine Corpus Cancer AJCC v7 automatically

Every clearance here is in the API, with alerts when new ones post.